Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Curis and Genentech in Hedgehog pathway deal for cancer

Executive Summary

Tissue repair and regeneration company Curis has licensed Genentech rights to its preclinical small-molecule and antibody Hedgehog pathway inhibitors for the development of cancer therapeutics.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register